Nexalin Technology (NXL) Long-Term Investments (2023 - 2024)
Nexalin Technology (NXL) recorded quarterly Long-Term Investments of $864.0 in Q4 2024, down 99.14% quarter-over-quarter from $100651.0 in Q3 2024, and down 99.1% on a YoY basis from $96000.0 in Q1 2024.
Nexalin Technology (NXL) Long-Term Investments (2023 - 2024) Analysis & Trends
Nexalin Technology's Long-Term Investments history runs 2 years deep, the most recent figure standing at $864.0 for Q4 2024.
- In Q4 2024, Long-Term Investments fell 99.1% year-over-year to $864.0; the TTM figure through Dec 2024 stood at $864.0 (down 99.1% YoY), while the FY2024 annual figure was $864.0, down 99.1% from the prior year.
- Long-Term Investments was $864.0 for Q4 2024 at Nexalin Technology, down from $100651.0 in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $101783.0 in Q1 2024 to a low of $864.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | 1.09 Bn |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | - |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | 285.60 Mn |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | - |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 166.25 Mn |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | - |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | - |
| 10 | Nexalin Technology | 8.72 Mn | 6.01 Mn | 13,133.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 864.00 |
| Sep 30, 2024 | 100,651.00 |
| Jun 30, 2024 | 100,492.00 |
| Mar 31, 2024 | 101,783.00 |
| Dec 31, 2023 | 96,000.00 |
| Sep 30, 2023 | 96,000.00 |